Patents Assigned to I.E.R.F.C. Europ. Inst. for Cystic. Fibrosis Res.
  • Combined therapy for cystic fibrosis
    Patent number: 9730922
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: August 15, 2017
    Assignee: I.E.R.F.C. Europ. Inst. for Cystic. Fibrosis Res.
    Inventors: Luigi Maiuri, Valeria Raia, Fabio Borella, Guido Kroemer